Primary Lateral Sclerosis
21
7
9
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (21)
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Phenotype, Genotype and Biomarkers 2
Clinical Procedures to Support Research in ALS
Spastic Paraplegia - Centers of Excellence Research Network
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Imaging Biomarkers in ALS
TRIAL READY (Clinical Trial Readiness)
Digital Assessment of Speech and Fine Motor Control in ALS
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis
Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
Answer ALS: Individualized Initiative for ALS Discovery
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease